Modular Medical (MODD) - רווח נקי למניה (EPS TTM)

Risks of FDA approval delays and pre-commercial stage losses create uncertainty. The 12-month net income per share snapshot helps track dynamics, where the current level is -10.19. Modular Medical is developing affordable insulin pumps for the mass market, creating compact and intuitive devices that make diabetes therapy as unobtrusive as possible in daily life.

Investors are assessing the fundamental stability of Modular Medical (MODD) through the lens of real return on equity. The eps_ttm_co metric measures the total annual net income per share, excluding the impact of equity dilution. By analyzing the current annual net income per share, one can identify the trend reversal point. Inelastic demand for affordable insulin pumps creates a foundation for the growth of this indicator. An increase in profit will confirm the effective monetization of the company's unique pricing power.